Childhood obesity at the crossroads of science and social justice
Patient safety issues in the GLP-1 space this week The U.K.'s Manchester Evening News reported on marketers promoting retatrutide to millions of users on social media despite the fact that the drug has not been approved anywhere in the world and cannot be obtained safely outside of Eli Lillys phase three clinical trials
Given that these results were coming from a randomised, double-blind clinical trial, the Parkinsons community got rather excited about them ( Click here to read a previous SoPD post about this particular trial)
They won't let you repost
It exists in both free and bound forms in the hypothalamus, limbic system, pituitary gland, and various peripheral organs, tissues, and fluids
Additive effects on weight loss were similarly demonstrated in the Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (SUSTAIN-9) and Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10) trials [103,104]
